Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Provided By GlobeNewswire
Last update: Jun 6, 2024
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement
0.37
-0.03 (-7.48%)
Find more stocks in the Stock Screener
MCRB Latest News and Analysis
5 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
6 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
